close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by eGenesis

eGenesis Announces IND Clearance for EGEN-2784 in Kidney Transplant and Landmark Patient Updates in Ongoing Expanded Access Study
From eGenesis
Via Business Wire
eGenesis Appoints Douglas Williams, Ph.D., and Adam Craig, M.D., Ph.D., to its Board of Directors
From eGenesis
Via Business Wire
eGenesis Appoints Dr. Jay Barth as Chief Medical Officer
From eGenesis
Via Business Wire
eGenesis and OrganOx Announce U.S. FDA Clearance of IND Application for the Treatment of Patients with Acute-On-Chronic Liver Failure
From eGenesis
Via Business Wire
eGenesis Announces Second Patient Successfully Transplanted with Genetically Engineered Porcine Kidney
From eGenesis
Via Business Wire
eGenesis Raises $191 Million Series D Financing to Advance Lead Program for Kidney Transplant
From eGenesis
Via Business Wire
eGenesis Announces World’s First Successful Transplant of Genetically Engineered Porcine Kidney in a Living Patient
From eGenesis
Via Business Wire
eGenesis and PorMedTec Announce Successful Production of Genetically Engineered Porcine Donors in Japan
From eGenesis
Via Business Wire
eGenesis and OrganOx Announce Successful Use of a Genetically Engineered Porcine Liver with a Human Donor
From eGenesis
Via Business Wire
eGenesis Presents Preclinical Data Demonstrating Recipient Survival and Compatibility with Genetically Engineered Porcine Kidneys at 2023 IPITA-IXA-CTRMS Joint Conference
From eGenesis
Via GlobeNewswire
eGenesis Announces Publication in Nature of Landmark Preclinical Data Demonstrating Long-Term Survival with Genetically Engineered Porcine Kidneys
From eGenesis
Via GlobeNewswire
eGenesis Announces Publication in Nature Communications Characterizing Renal Physiology and Endocrine Function in Non-Human Primates Post Xenograft Transplant
From eGenesis
Via GlobeNewswire
eGenesis Presents New Data on Long-Term Survival in Preclinical Kidney Xenotransplantation at American Transplant Congress 2023
From eGenesis
Via GlobeNewswire
eGenesis Announces Knut Niss as Chief Technology Officer
From eGenesis
Via GlobeNewswire
eGenesis and Eledon Pharmaceuticals Announce Collaboration for Use of Tegoprubart in Preclinical Xenotransplantation Studies
From eGenesis
Via GlobeNewswire
Tickers ELDN
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today